Innovating Works

FIBCAN

Financiado
Targeted strategies for prevention and treatment of fibrosis associated liver ca...
Advanced liver diseases such as cirrhosis and hepatocellular carcinoma (HCC) are major challenges for global health. HCC is the second leading and fastest rising cause of cancer death worldwide. Viral and metabolic liver disease a... Advanced liver diseases such as cirrhosis and hepatocellular carcinoma (HCC) are major challenges for global health. HCC is the second leading and fastest rising cause of cancer death worldwide. Viral and metabolic liver disease are the main risk factors for HCC, which nearly always arises in advanced liver fibrosis. For metabolic liver disease approved therapies are absent. Cure or suppression of viral infection cannot eliminate the HCC risk in patients with advanced fibrosis. Despite significant progress, therapeutic options for established HCC are still limited in efficacy and safety. Importantly, patient survival in HCC is dependent on the underlying fibrotic liver disease which is not targeted by approved HCC therapies. Addressing these unmet medical needs, FIBCAN aims to identify urgently needed targets for prevention and treatment of fibrosis-driven liver cancer. A key focus of FIBCAN will be the investigation of Claudin-1 as a previously undiscovered target for prevention and treatment of fibrosis-driven HCC. Our own data obtained in patient-derived model systems and tissues provide solid evidence that Claudin-1 is implicated in liver fibrosis and hepatocarcinogenesis, and overall and liver-specific patient death. To discover novel targets, we will apply a liver disease discovery platform modeling the clinical cell circuits of cirrhotic patients progressing to HCC combined with single cell RNA-seq and spatial transcriptomics of patient tissues. Proof-of-concept studies of target-specific compounds combined with biomarker discovery in cutting-edge patient-derived model systems will deliver novel strategies for further clinical development. A strong collaboration with pharma will lead to rapid translation of the FIBCAN program into the clinic. By delivering urgently needed therapeutic strategies for advanced liver disease and HCC, this proposal will have a marked impact on the management and outcome of patients with advanced liver disease in Europe and beyond. ver más
30/06/2027
INSERM
2M€
Duración del proyecto: 69 meses Fecha Inicio: 2021-09-27
Fecha Fin: 2027-06-30

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2021-09-27
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
ERC-2020-ADG: ERC ADVANCED GRANT
Cerrada hace 4 años
Presupuesto El presupuesto total del proyecto asciende a 2M€
Líder del proyecto
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER... No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5